Portage Biotech Inc. (NASDAQ:PRTG) Short Interest Update

Portage Biotech Inc. (NASDAQ:PRTG) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 13,800 shares, a decrease of 20.7% from the February 28th total of 17,400 shares. Based on an average trading volume of 86,500 shares, the days-to-cover ratio is presently 0.2 days. Approximately 8.4% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Portage Biotech stock. Virtu Financial LLC acquired a new stake in Portage Biotech Inc. (NASDAQ:PRTG) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned about 1.04% of Portage Biotech at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.36% of the company’s stock.

Portage Biotech Trading Down 10.7 %

Shares of PRTG stock traded down $0.99 on Tuesday, reaching $8.26. The company’s stock had a trading volume of 265,993 shares, compared to its average volume of 771,230. The stock’s fifty day simple moving average is $4.62 and its 200-day simple moving average is $5.09. Portage Biotech has a 1 year low of $2.10 and a 1 year high of $23.01. The company has a market capitalization of $8.66 million, a price-to-earnings ratio of -0.20 and a beta of 1.29.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.